Live tape
Top 8, mentions 7d14,365NVDA4,867 mentions▲ +0.04GOOGL2,064 mentions▲ +0.04SPY1,738 mentions▲ +0.06QQQ1,554 mentions▲ +0.05AMD1,212 mentions▲ +0.08SPCX1,112 mentions▲ +0.05TSLA956 mentions▲ +0.04SNDK862 mentions▲ +0.06

Equity · Healthcare

ELVN

NASDAQ

Enliven Therapeutics (ELVN)

53 USD +4.32% vs prior close
Enliven Therapeutics, Inc. price graph

This price chart is drawn by TradingView, from their own data, in an embed loaded from their servers.

Track this symbol on TradingView
Market cap
3.9B USD
EPS, diluted, year to Dec 2025
−1.83 USD
52-week range
15 USD – 53.13 USD
Avg volume
448.5K

as of Jul 17, 2026

Have Enliven Therapeutics (ELVN) insiders bought or sold shares recently?

In the 90 days to 10 Nov 2026, Enliven Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 7 Oct 2025, show no open-market purchase.

Form 4, 90 days to 10 Nov 2026, newest reported trade 19 Oct 2026

0buys
7sells
$2.23Mnet sold
7other filings
Have Enliven Therapeutics (ELVN) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
19 Oct 2026Collins Helen LouiseCHIEF MEDICAL OFFICERSell5,000192K USD
19 Oct 2026Hohl BenjaminCHIEF FINANCIAL OFFICERSell6,018232K USD
01 Oct 2026Garland J. ScottDirectorSell13,000607K USD
17 Sep 2026Collins Helen LouiseCHIEF MEDICAL OFFICERSell5,000252K USD
17 Sep 2026Hohl BenjaminCHIEF FINANCIAL OFFICERSell6,018303K USD
17 Aug 2026Collins Helen LouiseCHIEF MEDICAL OFFICERSell5,000293K USD
17 Aug 2026Hohl BenjaminCHIEF FINANCIAL OFFICERSell6,018353K USD
Sold7 open-market sales46,054$2.23M
7 other filings in the window: grants, exercises, tax withholding and transfers, not trades
Have Enliven Therapeutics (ELVN) insiders bought or sold shares recently?
ReportedInsiderTypeSharesValue
30 Oct 2026Kunkel Lori AnneDirectorOption exercise11,041138K USD
19 Oct 2026Collins Helen LouiseCHIEF MEDICAL OFFICEROption exercise5,00012K USD
19 Oct 2026Hohl BenjaminCHIEF FINANCIAL OFFICEROption exercise6,01889K USD
01 Oct 2026Garland J. ScottDirectorOption exercise13,000201K USD
17 Sep 2026Collins Helen LouiseCHIEF MEDICAL OFFICEROption exercise5,00012K USD
17 Sep 2026Hohl BenjaminCHIEF FINANCIAL OFFICEROption exercise3,98259K USD
17 Aug 2026Collins Helen LouiseCHIEF MEDICAL OFFICEROption exercise5,00012K USD

Which funds hold Enliven Therapeutics (ELVN)?

8 of the 45 institutional funds we track reported a Enliven Therapeutics position for the quarter ended 30 Jun 2026 — a combined 248.3M USD; the latest of those filings landed 02 Sep 2026.

Form 13F

Which funds hold Enliven Therapeutics (ELVN)?
FundPositionSharesValueShares q/q
Citadel AdvisorsHeld (±25%)2,068,992105.0M USD+18.6%
Baker Bros. AdvisorsHeld (±25%)905,19145.9M USD
Balyasny Asset ManagementAdded607,18930.8M USD+95.9%
Marshall WaceNew position532,26927.0M USD
Millennium ManagementHeld (±25%)411,36220.9M USD+19.1%
D. E. Shaw & Co.Added305,70315.5M USD+58.0%
Tudor Investment CorpNew position40,1182.0M USD
Two Sigma InvestmentsNew position22,7581.2M USD

What has been filed or recorded for Enliven Therapeutics (ELVN)?

The filings we hold for Enliven Therapeutics, newest first: 1 fails-to-deliver day, 6 quarterly earnings reports, 2 annual reports and 4 reported financial figures, the latest dated 02 Oct 2026. No next earnings date is announced in SEC filings yet.

What has been filed or recorded for Enliven Therapeutics (ELVN)?
And
02 Oct 2026Fails to deliverShares failed to deliver2,503 shares116K USD notional · 0.003% of shares out
30 Sep 2026Quarterly earningsQ3 2026 reportedEPS −0.36 USD
30 Sep 2026FinancialsTotal assets897.2M USDat period end
30 Sep 2026FinancialsTotal equity876.9M USDat period end
30 Jun 2026Quarterly earningsQ2 2026 reportedEPS −0.49 USD
31 Mar 2026Quarterly earningsQ1 2026 reportedEPS −0.38 USD
31 Dec 2025Annual reportFY 2025 reportedEPS −1.83 USD
31 Dec 2025FinancialsNet income−103.7M USDfiscal year
31 Dec 2025FinancialsDiluted EPS−1.83 USDfiscal year
30 Sep 2025Quarterly earningsQ3 2025 reportedEPS −0.32 USD
30 Jun 2025Quarterly earningsQ2 2025 reportedEPS −0.49 USD
31 Mar 2025Quarterly earningsQ1 2025 reportedEPS −0.57 USD
31 Dec 2024Annual reportFY 2024 reportedEPS −1.89 USD

What do people ask about Enliven Therapeutics (ELVN)?

From live data
What is Enliven Therapeutics’ market cap?3.9B

Enliven Therapeutics is worth 3.9B USD by market value as of 17 Jul 2026, which is the share price times the shares on issue from its SEC filings.

Have Enliven Therapeutics insiders bought or sold shares recently?7 sales

In the 90 days to 10 Nov 2026, Enliven Therapeutics insiders reported 7 open-market sales and no purchases (SEC Form 4); the filings we hold, back to 7 Oct 2025, show no open-market purchase. A further 7 filings were grants, awards, gifts or exercises rather than open-market trades. See Insiders

Which funds own Enliven Therapeutics?8 of 45

8 of the 45 funds we track reported a Enliven Therapeutics position for the quarter ended 30 Jun 2026, per their SEC Form 13F filings. The largest reported positions were Citadel Advisors, Baker Bros. Advisors and Balyasny Asset Management. See Funds

When did Enliven Therapeutics last report earnings?−0.36

Enliven Therapeutics last reported earnings on 30 Sep 2026 for Q3 2026, with EPS of −0.36 USD; no next date is announced in SEC filings yet. See Filings

Answers are generated from the live figures on this page — Reddit crowd data, SEC filings and open company records — and update as the data does.

References
  1. Finazonprior-day close, indicative (IEX-derived, not the official close)
  2. TradingViewthe price chart widget, drawn by TradingView from their own data
  3. SEC EDGARForm 4 filings (insider transactions)
  4. SEC EDGAR13F filings
  5. SECSEC fails-to-deliver (CNS) data
  6. SEC EDGARXBRL company facts, latest period ended 30 Sep 2026
  7. SEC EDGARreported earnings figures and scheduled report dates
  8. SEC EDGARValuation computed from SEC EDGAR filings